No disease or health problem is being investigated. Investigation of the effect of starch, MCTs and various types of dietary fibre on the metabolism of healthy participants.
Conditions
Interventions
Group 1: Pudding as an intervention meal, consisting of water, maize starch, milk (1.5% fat), flavouring, sweetener, medium-chain triglycerides (MCT) (0.3 g/kg body weight*), beta-glucan (0.15 g/kg bo
Sponsors
FH Münster
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: - Normal weight (BMI = 18.5 – 25.0)
Exclusion criteria
Exclusion criteria: - Pregnancy, breastfeeding - Presence of a serious or chronic condition causing significant health impairments (e.g. cancer, cardiovascular disease, thyroid disorders, bowel diseases) or an acute illness at the time of the examination - Known metabolic disorder (e.g. lipid metabolism disorder, type 1 or 2 diabetes mellitus) - Taking medication (exception: contraceptives) - Consumption of MCT within the past 4 weeks - Mental or speech impairments - Low-carb or other dietary regimens involving a sustained reduction in carbohydrate intake (EFSA: at least 45% of energy from carbohydrates) - Diagnosed eating disorders - Known swallowing disorders or conditions involving clinically significant dysphagia or an increased risk of aspiration - Donation of whole blood within the last 3 months and/or donation of blood plasma within the last 4 weeks prior to the start of the study - Intolerance to sucralose or other sweeteners - Difficult or impossible venous blood sampling due to anatomical conditions or other medical reasons (e.g. veins that are difficult to locate, fragile or severely sclerosed) - Severe fear of blood sampling or injections - Functional bowel disorders (particularly irritable bowel syndrome), lactose intolerance, milk protein allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ß-hydroxybutyrate (ßHB; tmax) in venous blood, measured before the intervention (t0) and at 30, 60, 120, 180, 240 and 300 minutes (t1–t6) after the intervention. Blood samples are taken via an indwelling venous catheter. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Body weight measured on scales prior to the intervention days - Height measured using a stadiometer prior to the intervention days - Body Mass Index (BMI) calculated from body weight and height prior to the intervention days - Body composition measured using bioelectrical impedance analysis (BIA) prior to the intervention days - Insulin, glucose and essential/non-essential fatty acids in venous blood, measured before the intervention (t0) and at 30, 60, 120, 180, 240 and 300 minutes (t1–t6) after the intervention - Ketone bodies in interstitial fluid via a continuous ketone body sensor, continuous measurement - Glucose in interstitial fluid via a continuous glucose sensor, continuous measurement - Acetone in exhaled air, measured before the intervention (t0) and at 30, 60, 120, 180, 240 and 300 minutes (t1–t6) after the intervention - Glucose and ßHB in capillary blood, measured before the intervention (t0) and at 30, 60, 180 and 300 minutes (t0, t1, t2, t4, t6) after the intervention - Ketone bodies, leukocytes, nitrite, pH, protein, glucose, urobilinogen, bilirubin, and blood in urine via collection of spontaneous urine and analysis with urine test strips between t0 and t6 - Resting energy expenditure (REE) and macronutrient contributions to energy metabolism via indirect calorimetry before the intervention days and up to twice per intervention day - Stool consistency according to the Bristol Stool Chart: assessed once to determine the usual stool consistency prior to the first intervention, and retrospectively for the first bowel movement following each intervention | — |
Countries
Germany
Contacts
Public ContactTobias Fischer
FH Münster
Outcome results
None listed